In Vitro fertilization and adverse obstetric and perinatal outcomes

Sullivan-Pyke, Chantae S.; Senapati, Suneeta; Mainigi, Monica; Barnhart, Kurt T.

doi:10.1053/j.semperi.2017.07.001

Cited by 105 publications

(94 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Few studies have investigated the ART parameters associated with the risk of perinatal obstetric outcomes . Successful ART depends on the quality of the embryo and endometrial receptivity at the time of pre‐implantation .…”

Section: Discussionmentioning

confidence: 99%

Embryo transfer associated with hormone replacement therapy cycles using assisted reproductive technology increases placenta accreta spectrum

Sakai

Ono

Iizuka

et al. 2019

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim: To evaluate obstetric outcomes in embryo transfer (ET) during estrogen with progestin hormone replacement therapy (HRT) cycles using assisted reproductive technology (ART). Methods: Of the 118 singleton pregnancies conceived with ART and delivered between January 2015 and December 2017, we reviewed the data of 87 cases that had information on HRT at the time of ET. Data on pregnancy outcomes included the presence of small for gestational age fetuses, hypertensive disorders of pregnancy, placenta previa (including low-lying placenta), placental abruption and placenta accreta spectrum (including placenta accreta, placenta increta and placenta percreta). We investigated the relationship between HRT cycles and adverse placental outcomes (placenta accreta spectrum, placental abruption, placenta previa, hypertensive disorders of pregnancy and small for gestational age fetuses). We then analyzed the associations that correlated with adverse placental outcomes. Results: Patients with ET during HRT cycles were more likely to have placenta accreta spectrum. During the study period, 87 out of 118 singleton live births using ART had information on HRT (60 HRT cycles and 27 ovulation cycles). The incidence of placenta accreta spectrum was significantly higher in the HRT cycle group than in the ovulation cycle group (HRT cycle, 31.7% [19 of 60] vs ovulation cycle, 7.4% [2 of 27]; P < 0.01). Conclusion: The obstetric outcomes occurring in pregnancies involving HRT use may differ among ET cycles. ET during HRT cycles were associated with adverse obstetric outcomes due to placenta accreta spectrum. The potential interaction between HRT cycles and adverse placental events is novel and warrants further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Embryo transfer associated with hormone replacement therapy cycles using assisted reproductive technology increases placenta accreta spectrum

Sakai

Ono

Iizuka

et al. 2019

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…The exact mechanism is unclear. However, altered gamete environment due to hormonal stimulation, physical manipulation, and embryo culture during the ICSI procedure may initiate changes, such as epigenetic modifications in growth and development genes that are responsible for such adverse outcomes (6,7). Although these syndromes as an outcome of ICSI are rare, further studies are needed to understand the molecular basis not only for healthcare professionals but also for the couples considering fertility treatment.…”

Section: Discussionmentioning

confidence: 99%

Co-existence of Goldenhar and Klinefelter Syndromes in a Patient Born Following ICSI

Zeybek¹,

Sarikepe²,

Bağcı³

et al. 2018

Erciyes Med J

View full text Add to dashboard Cite

Intracytoplasmic sperm injection (ICSI) is a widespread and powerful method enabling men with low sperm quantity and quality to become fathers. However, compared with naturally conceived children, there are increased risks of problems, such as congenital malformations, chromosomal abnormalities, infertility, epigenetic diseases, and delayed neuropsychological development in the offspring. We present the case of 6-year-old male patient born following ICSI with clinical and radiological features of Goldenhar syndrome as well as a history of surgery for unilateral cryptorchidism. His karyotyping showed a chromosomal constitution of 47, XXY. Clinicians should be aware of the risks of an increasing number of patients born following ICSI to maximize children's health and welfare.

show abstract

“…(55)(56)(57)(58)(59)(60)(61)(62)(63)(64)(65) It is recognized that these women are at an increased risk of placenta-associated complications of pregnancy, including hypertensive disorder of pregnancy, (66)(67)(68)(69) preterm delivery, (70,71) and fetal growth restriction. (70,72) The objective of this study was to perform a systematic review and meta-analysis to estimate the effect of low-dose aspirin initiated at <11 weeks' gestation on the risk of preeclampsia, gestational hypertension, or any hypertensive disorder of pregnancy.…”

Section: Introductionmentioning

confidence: 99%

Does low-dose aspirin initiated before 11 weeks’ gestation reduce the rate of preeclampsia?

Chaemsaithong

Cuenca-Gomez

Plana

et al. 2020

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

Condensation: Aspirin given at <11 weeks' gestation in high risk women does not reduce the risk of preeclampsia and gestational hypertension but may reduce the risk of preterm delivery. Short title: Early aspirin administration and preeclampsia PROSPERO registration number: CRD42019125006 AJOG at a Glance: Why was this study conducted? • To perform a systematic review and meta-analysis to evaluate the effect of lowdose aspirin initiated at <11 weeks' gestation on the risk of preeclampsia, gestational hypertension, or any hypertensive disorder of pregnancy. Secondary outcomes included preterm delivery at <37 weeks' gestation and fetal growth restriction. Key findings • The administration of low-dose aspirin at <11 weeks' gestation in women with a history of recurrent pregnancy loss, women who had undergone in vitro fertilization or women with thrombophilia or antiphospholipid syndrome was associated with a non-significant decrease in the risk of preeclampsia, gestational hypertension, and any hypertensive disorder of pregnancy. • Early low-dose aspirin reduced the risk of preterm delivery but had no impact on the risk of fetal growth restriction. • Except for preterm delivery and any hypertensive disorder of pregnancy, sensitivity analysis demonstrated similar observations; confirming the robustness of our analysis. What does this add to what is known? • Administration of low-dose aspirin at <11 weeks' gestation to high risk women does not reduce the risk of preeclampsia, gestational hypertension, any hypertensive disorder of pregnancy and fetal growth restriction but might reduce the risk of preterm delivery at <37 weeks of gestation. ABSTRACT OBJECTIVE DATA: Pre-conception or early administration of low-dose aspirin might improve endometrial growth, placental vascularization and organogenesis. Most studies have evaluated the potential benefit of pre-conception or early administration of low-dose aspirin in women with a history of recurrent pregnancy loss, women who have undergone in vitro fertilization or women with thrombophilia or antiphospholipid syndrome. These women are at an increased risk of placenta-associated complications of pregnancy, including preeclampsia, preterm delivery and fetal growth restriction. STUDY: We performed a systematic review and meta-analysis to evaluate the effect of low-dose aspirin initiated at <11 weeks' gestation on the risk of preeclampsia, gestational hypertension, or any hypertensive disorder of pregnancy. Secondary outcomes included preterm delivery at <37 weeks' gestation and fetal growth restriction. STUDY APPRAISAL AND SYNTHESIS METHODS: We searched in MEDLINE via PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.Gov and the World Health Organization International Clinical Trials Registry Platform (WHO-ICTRP) from 1985 to November 2018. Entry criteria were randomized controlled trials evaluating the effect of aspirin administered at <11 weeks' gestation in preventing preeclampsia and/or hypertensive disorders in pregnancy or improvi...

show abstract

In Vitro fertilization and adverse obstetric and perinatal outcomes

Cited by 105 publications

References 87 publications

Embryo transfer associated with hormone replacement therapy cycles using assisted reproductive technology increases placenta accreta spectrum

Embryo transfer associated with hormone replacement therapy cycles using assisted reproductive technology increases placenta accreta spectrum

Co-existence of Goldenhar and Klinefelter Syndromes in a Patient Born Following ICSI

Does low-dose aspirin initiated before 11 weeks’ gestation reduce the rate of preeclampsia?

Contact Info

Product

Resources

About